Mark Singleton - 02 Feb 2022 Form 4 Insider Report for GreenLight Biosciences Holdings, PBC

Role
VP of Technology
Signature
/s/ David Kennedy, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
02 Feb 2022
Net transactions value
$0
Form type
4
Filing time
04 Feb 2022, 18:28:22 UTC
Next filing
08 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GRNA Stock Option (Right to Buy) Award +192,936 192,936 02 Feb 2022 Common Stock 192,936 $1.23 Direct F1, F2
transaction GRNA Stock Option (Right to Buy) Award +13,399 13,399 02 Feb 2022 Common Stock 13,399 $1.23 Direct F2, F3
transaction GRNA Stock Option (Right to Buy) Award +126,424 126,424 02 Feb 2022 Common Stock 126,424 $2.61 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying the option vested or shall vest on February 9, 2022 and the remainder of the shares vested or shall vest in 36 equal monthly installments thereafter, starting March 9, 2022.
F2 This option was issued pursuant to the terms of a business combination agreement involving the Issuer and GreenLight Biosciences, Inc. in exchange for a comparable option previously issued by such company.
F3 25% of the shares underlying the option vested or shall vest on February 9, 2022 and the remainder of the shares vested or shall vest in 36 equal monthly installments thereafter, starting March 9, 2022.
F4 25% of the shares underlying the option vested or shall vest on June 30, 2022 and the remainder of the shares vested or shall vest in 36 equal monthly installments thereafter, starting July 30, 2022.